Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN2D known ✓ | O15399 | 1/20 | 0.56 |
| ▸ | GRIN3B known ✓ | O60391 | 1/20 | 0.56 |
| ▸ | GRIN1 known ✓ | Q05586 | 1/20 | 0.56 |
| ▸ | GRIN2A known ✓ | Q12879 | 1/20 | 0.56 |
| ▸ | GRIN2B known ✓ | Q13224 | 1/20 | 0.56 |
| ▸ | GRIN2C known ✓ | Q14957 | 1/20 | 0.56 |
| ▸ | GRIN3A known ✓ | Q8TCU5 | 1/20 | 0.56 |
| ▸ | PTGS1 known ✓ | P23219 | 1/20 | 0.48 |
| ▸ | GSR | P00390 | 2/20 | 0.65 |
| ▸ | GRM8 | O00222 | 1/20 | 0.56 |
| ▸ | GRM6 | O15303 | 1/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.56 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.56 |
| ▸ | GRM5 | P41594 | 1/20 | 0.56 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.56 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.56 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.56 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.56 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.56 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL2398999 | 1.00 | — | — | |
| Hydrochloric Acid SCHEMBL318747 | 1.00 | GSR (0.65) | GSRGRM8GRM6GRIN2DGRIN3B | |
| Hydrochloric Acid SCHEMBL29401163 | 1.00 | GSR (0.65) | GSRGRM8GRM6GRIN2DGRIN3B | |
| Hydrochloric Acid SCHEMBL2462827 | 1.00 | — | — | |
| SCHEMBL34706 | 0.97 | — | — | |
| SCHEMBL288792 | 0.97 | — | — | |
| SCHEMBL34705 | 0.97 | — | — | |
| SCHEMBL29479228 | 0.97 | — | — | |
| Bromide SCHEMBL29401581 | 0.94 | — | — | |
| Bromide SCHEMBL7013646 | 0.94 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-121758308-B | Preparation method of L-2, 4-diaminobutyric acid dihydrochloride | 山东省农药科学研究院 | 2026-05-19 | — | — | CN | claimed |
| CN-122036624-A | Preparation method of high-purity exendin | 辽宁大学 | 2026-05-15 | — | — | CN | claimed |
| CN-120004697-A | Preparation method of OrgVO material and application of OrgVO material as secondary battery anode material | 同济大学 | 2025-05-16 | — | — | CN | claimed |
| CN-121758308-B | Preparation method of L-2, 4-diaminobutyric acid dihydrochloride | 山东省农药科学研究院 | 2026-05-19 | — | — | CN | disclosed |
| CN-121758308-B | Preparation method of L-2, 4-diaminobutyric acid dihydrochloride | 山东省农药科学研究院 | 2026-05-19 | — | — | CN | disclosed |
| CN-121758308-B | Preparation method of L-2, 4-diaminobutyric acid dihydrochloride | 山东省农药科学研究院 | 2026-05-19 | — | — | CN | disclosed |
| CN-122036624-A | Preparation method of high-purity exendin | 辽宁大学 | 2026-05-15 | — | — | CN | disclosed |
| CN-122036624-A | Preparation method of high-purity exendin | 辽宁大学 | 2026-05-15 | — | — | CN | disclosed |
| CN-121758308-A | Preparation method of L-2, 4-diaminobutyric acid dihydrochloride | 山东省农药科学研究院 | 2026-03-31 | — | — | CN | disclosed |
| CN-121758308-A | Preparation method of L-2, 4-diaminobutyric acid dihydrochloride | 山东省农药科学研究院 | 2026-03-31 | — | — | CN | disclosed |
| CN-120004697-A | Preparation method of OrgVO material and application of OrgVO material as secondary battery anode material | 同济大学 | 2025-05-16 | — | — | CN | disclosed |
| WO-2020201041-A2 | GLUCOSE SENSITIVE INSULIN DERIVATIVES | NOVO NORDISK A/S (DK) | 2020-10-08 | — | — | WO | disclosed |
| EP-3707145-A1 | GLUCOSE-SENSITIVE ALBUMIN-BINDING DERIVATIVES | Novo Nordisk A/S (DK) | 2020-09-16 | — | — | EP | disclosed |
| US-20130190289-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OR PREVENTION OF FLAVIVIRUS INFECTIONS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-07-25 | — | — | US | disclosed |
| EP-2585447-A2 | COMPOUNDS AND METHODS FOR THE TREATMENT OR PREVENTION OF FLAVIVIRUS INFECTIONS | Vertex Pharmaceuticals Incorporated (US) | 2013-05-01 | — | — | EP | disclosed |
| CN-102952082-A | Manual synthetic method for tetrahydropyrimidine hydrochloride | JINAN HUANTAI MEDICAL TECHNOLOGY CO LTD | 2013-03-06 | — | — | CN | disclosed |
| US-20120122820-A1 | PRODRUGS AND THE USE THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT | 2012-05-17 | — | — | US | disclosed |
| WO-2012006055-A2 | COMPOUNDS AND METHODS FOR THE TREATMENT OR PREVENTION OF FLAVIVIRUS INFECTIONS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-01-12 | — | — | WO | disclosed |
| US-6579696-B1 | Comprising diaminobutyric acid having a gamma amino group and amino acid selected from cysteine, alanine and lysine; use in prevention and treatment of sepsis | PROMEGA CORPORATION | 2003-06-17 | — | — | US | disclosed |
| US-5998381-A | PROVIDING SUBJECT WITH BACTERIAL DISEASE WITH FIMBRIAE BINDING COMPOUND COMPRISING ANOMERIC MANNOSE, AN AROMATIC OR HETEROAROMATIC RING ATTACHED TO MANNOSE BY GLYCOSIDIC LINKAGE AND FUNCTIONAL GROUP PROVIDING MODIFICATION SITE | OPHIDIAN PHARMACEUTICALS, INC. (US) | 1999-12-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120122820-A1 | PRODRUGS AND THE USE THEREOF | TPMT, DPP4, PYGL | GRIN2D 3959/4885GRIN3B 3084/4885GRIN1 3024/4885 |
| US-20130190289-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OR PREVENTION OF FLAVIVIRUS INFECTIONS | SLC10A1, ACE, CEL | GRIN2D 4507/4885GRIN3B 3764/4885GRIN1 3044/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.